NCT03471117View on ClinicalTrials.gov

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Chronic Kidney Diseases
Interventions
DRUG

Pioglitazone

Pioglitazone 15mg daily for 1 month

OTHER

Placebo

Placebo pills for 1 month

Trial Locations (2)

75390

RECRUITING

UT Southwestern, Dallas

76010

RECRUITING

University of Texas at Arlington, Arlington

All Listed Sponsors
collaborator

University of Texas, Southwestern Medical Center at Dallas

OTHER

lead

The University of Texas at Arlington

OTHER